Related Experiment Video
Updated: Feb 16, 2026

Three-dimensional Alginate-bead Culture of Human Pituitary Adenoma Cells
Published on: February 18, 2016
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway
Junwen Wang1, Zhuo Zhang1, Ran Li1
1Sino-German Neuro-Oncology Molecular Laboratory, Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Aim:
Triptolide, an effective component derived from Tripterygium wilfordii, has been well recognized to process a broad-spectrum antitumor activities in various tumor types. However, the potential role of triptolide in pituitary adenomas remains unknown. The aim of this study was to investigate the precise role of triptolide and underlying mechanism in regulating pituitary adenoma cell viability, migration and invasion.
Main Methods:
We use mouse pituitary adenoma cells (TtT/GF and AtT20 cells) as the experiment model and treated them with varying concentrations of triptolide. The corresponding inhibitory effects on cell viability, migration, invasion and apoptosis were examined respectively, and the underlying mechanism was determined by investigating ADAM12 (a disintegrin and metalloprotease 12)/EGFR signaling.
Key Findings:
Triptolide significantly inhibited cell viability, migration and invasion in TtT/GF and AtT20 cells in a dose-dependent manner. Mechanistically, triptolide significantly reduced ADAM12 expression at protein levels and attenuated ADAM12/EGFR signaling. Meanwhile, triptolide treatment combined with ADAM12 silencing enhanced the suppression effects on cell viability, migration and invasion, and those effects were restored following ADAM12-rescued. Moreover, triptolide suppressed the tumorigenesis of TtT/GF and AtT20 cells in vivo.
Significance:
Our research provides evidence that triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway. These findings suggest a potential role for triptolide in treating pituitary adenomas.
Insights
Triptolide effectively inhibits pituitary adenoma cell growth, migration, and invasion by targeting the ADAM12/EGFR pathway. This natural compound shows promise for treating pituitary adenomas.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Triptolide from Tripterygium wilfordii exhibits broad-spectrum antitumor activity.
- The role of triptolide in pituitary adenomas is currently unknown.
Purpose of the Study:
- To investigate the effect of triptolide on pituitary adenoma cell viability, migration, and invasion.
- To elucidate the underlying molecular mechanism involving ADAM12/EGFR signaling.
Main Methods:
- Mouse pituitary adenoma cell lines (TtT/GF and AtT20) were treated with varying triptolide concentrations.
- Assessed effects on cell viability, migration, invasion, and apoptosis.
- Investigated the role of ADAM12 (a disintegrin and metalloprotease 12)/EGFR signaling.
Main Results:
- Triptolide significantly inhibited cell viability, migration, and invasion in a dose-dependent manner.
- Triptolide reduced ADAM12 expression and attenuated ADAM12/EGFR signaling.
- Triptolide suppressed pituitary adenoma cell tumorigenesis in vivo.
Conclusions:
- Triptolide inhibits pituitary adenoma progression through the ADAM12/EGFR pathway.
- Triptolide demonstrates potential as a therapeutic agent for pituitary adenomas.
Related Concept Videos
Hypothalamic-Pituitary Axis
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway

